oxaliplatin at antigen release, addressing threshold drift
oxaliplatin (immunogenic chemotherapy) acts at the antigen release step of the cancer-immunity cycle. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation.
What this is
The Living Scorecard is Encounter's open record of structural predictions. Each hypothesis names a candidate intervention, where in the cycle it is predicted to act, the failure mode it is predicted to address, and the evidence available when the prediction was made.
Predictions are locked with timestamps before they can be tested. Encounter generates them daily, many more than any one person can chase, so the field can see what the framework claims structurally, ahead of the data. Some will hold. Some will be refuted. Both stay on the page. The point is that each prediction is committed before the answer is known, so the data that arrives later can confirm or refute it.
Structural argument
At the antigen release step of the cancer-immunity cycle (capacitor regime, position P1), oxaliplatin acts via immunogenic chemotherapy. The failure mode is threshold drift: threshold moves out of reach of normal loading current. Capacitor sometimes fires, sometimes doesn't; unpredictable activation. The intervention's regime-type class lines up with the position's regime, and failure_threshold_drift belongs to that regime's failure set.
rule_r13(required) — Combinatorial candidate is grounded in R13's position-to-state table, which determines which interventions are structurally addressable at which positions.
Substrate
- Domain
- domain_cellular_biology
- Cycle
- cycle_l4_canonical
- Position(s)
- position_p1
- Failure modes
- failure_threshold_drift
Evidence at generation
"oxaliplatin" AND "cancer immunotherapy"
- PMID 34547082
Pancreatic Cancer: A Review.
- PMID 37165196
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.
- PMID 33253966
Pancreatic cancer-targeting exosomes for enhancing immunotherapy and reprogramming tumor microenvironment.
- PMID 36108810
Liposomal oxaliplatin prodrugs loaded with metformin potentiate immunotherapy for colorectal cancer.
- PMID 37030544
Enhancing anti-tumor immunity through liposomal oxaliplatin and localized immunotherapy via STING activation.
Targets: CHEMBL2311221
inhibitor
oxaliplatin cancer immunotherapy
- NCT05158621
Metastatic Colorectal Cancer
Primary: Primary
- NCT05400902
Intrahepatic Cholangiocarcinoma
Primary: Response Rate
- NCT06048081
Locally Advanced Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma Cancer
- NCT04150640
Esophageal Adenocarcinoma
Primary: Cohort 1: Objective Response Rate (ORR)
- NCT03382600
Gastric Cancer
Primary: Objective Response Rate (ORR) According to Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1) Assessed by Blinded Independent Central Review (BICR)
Status timeline
- Draft2026-05-29T18:08:09Z
Generated by combinatorial walker (v0.1.1; verb_target-aware, sub-regime failures). Awaiting operator review for the daily top-5 batch.
by system